US 12,326,404 B2
Method and system for detecting cancerous tissue and tumor margin using raman spectroscopy
Alan Kersey, South Glastonbury, CT (US); and Rishikesh Pandey, Unionville, CT (US)
Assigned to CytoVeris, Inc., Farmington, CT (US)
Appl. No. 17/427,391
Filed by CytoVeris Inc., Farmington, CT (US)
PCT Filed Jan. 31, 2020, PCT No. PCT/US2020/016196
§ 371(c)(1), (2) Date Jul. 30, 2021,
PCT Pub. No. WO2020/160462, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/874,694, filed on Jul. 16, 2019.
Claims priority of provisional application 62/799,233, filed on Jan. 31, 2019.
Prior Publication US 2022/0099580 A1, Mar. 31, 2022
Int. Cl. B01L 3/00 (2006.01); B01F 33/302 (2022.01); B01F 33/3033 (2022.01); B01L 7/00 (2006.01); C12Q 1/6848 (2018.01); C12Q 1/686 (2018.01); G01N 21/29 (2006.01); G01N 21/65 (2006.01); G01N 33/574 (2006.01); G01N 33/58 (2006.01)
CPC G01N 21/658 (2013.01) [G01N 33/574 (2013.01); G01N 33/587 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method for determining the presence or absence of cancerous cells within subject tissue, the method comprising:
providing a material that includes at least one type of peptide component configurable in a non-binding form when disposed in a neutral pH environment, and in a binding form when disposed in an acidic pH environment, wherein the peptide component is configured to produce a first Raman spectrum when subjected to one or more predetermined wavelengths of light;
wherein the peptide component includes a pH (low) insertion peptide (pHLIP) and a Raman Reporter (RR), the RR configured to produce the first Raman spectrum when subjected to the one or more predetermined wavelengths of light, and the first Raman spectrum is distinguishable from Raman spectra produced by the subject tissue when subjected to the one or more predetermined wavelengths of light; and
wherein the first Raman spectrum resides within a Raman silent region defined by a wavelength region within a range of about 1800 cm−1 to about 2800 cm−1;
administering the material to a subject tissue and allowing the material to reside with the subject tissue for an incubation period of time;
washing the subject tissue after the incubation period to remove any unbound peptide components;
interrogating the subject tissue with light at the one or more predetermined wavelengths of light produced by one or more light sources after the subject tissue has been washed after the incubation period;
sensing the subject tissue for light emitted from the subject tissue using one or more light detectors, the emitted light resulting from the light interrogation of the subject tissue, and producing signals representative of the sensed emitted light;
analyzing the signals representative of the sensed emitted light using an analyzer to determine a presence or absence of the first Raman spectrum produced by the peptide component when subjected to one or more predetermined wavelengths of light; and
determining the presence or absence of cancerous cells within the subject tissue based on the presence or absence of the first Raman spectrum within the sensed light emitted from the subject tissue.